BC Week In Review | May 19, 2014
Clinical News

CytoScan Dx Assay regulatory update

Affymetrix disclosed in its 1Q14 earnings that in March it received CE Mark approval in Europe for CytoScan Dx Assay, a postnatal assay to detect chromosomal variations that may be responsible for a child's developmental...
BC Week In Review | Jan 27, 2014
Clinical News

CytoScan Dx Assay regulatory update

Affymetrix said FDA approved its CytoScan Dx Assay to detect chromosomal variations that may be responsible for a child's developmental delay or intellectual disability. The company said the assay is intended for the postnatal detection...
Items per page:
1 - 2 of 2